Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complement in antibody-based tumor therapy.
Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Derer S, et al. Among authors: rosner t. Crit Rev Immunol. 2014;34(3):199-214. doi: 10.1615/critrevimmunol.2014009761. Crit Rev Immunol. 2014. PMID: 24941073 Review.
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.
Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T. Lohse S, et al. Among authors: rosner t. Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3. Cancer Res. 2016. PMID: 26634925
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T. Tammen A, et al. Among authors: rosner t. J Immunol. 2017 Feb 15;198(4):1585-1594. doi: 10.4049/jimmunol.1601268. Epub 2017 Jan 6. J Immunol. 2017. PMID: 28062698
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T. Lohse S, et al. Among authors: rosner t. Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. Br J Haematol. 2018. PMID: 28449349 Free article. No abstract available.
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
Wirt T, Rosskopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C. Wirt T, et al. Among authors: rosner t. Transfus Med Hemother. 2017 Sep;44(5):292-300. doi: 10.1159/000479978. Epub 2017 Sep 11. Transfus Med Hemother. 2017. PMID: 29070974 Free PMC article.
Antibody Isotypes for Tumor Immunotherapy.
Kretschmer A, Schwanbeck R, Valerius T, Rösner T. Kretschmer A, et al. Among authors: rosner t. Transfus Med Hemother. 2017 Sep;44(5):320-326. doi: 10.1159/000479240. Epub 2017 Sep 7. Transfus Med Hemother. 2017. PMID: 29070977 Free PMC article. Review.
82 results